MX2008006887A - Dentifrice composition free of abrasive material - Google Patents
Dentifrice composition free of abrasive materialInfo
- Publication number
- MX2008006887A MX2008006887A MXMX/A/2008/006887A MX2008006887A MX2008006887A MX 2008006887 A MX2008006887 A MX 2008006887A MX 2008006887 A MX2008006887 A MX 2008006887A MX 2008006887 A MX2008006887 A MX 2008006887A
- Authority
- MX
- Mexico
- Prior art keywords
- zinc
- dentifrice composition
- composition
- agents
- mixtures
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 126
- 239000000551 dentifrice Substances 0.000 title claims abstract description 30
- 239000003082 abrasive agent Substances 0.000 title claims abstract description 27
- 239000000463 material Substances 0.000 claims abstract description 61
- -1 phytic acid compound Chemical class 0.000 claims abstract description 29
- 239000004927 clay Substances 0.000 claims abstract description 20
- 229910052570 clay Inorganic materials 0.000 claims abstract description 20
- 235000002949 phytic acid Nutrition 0.000 claims abstract description 17
- 229950002499 Fytic acid Drugs 0.000 claims abstract description 16
- 229940068041 Phytic Acid Drugs 0.000 claims abstract description 13
- 239000000467 phytic acid Substances 0.000 claims abstract description 13
- 239000002798 polar solvent Substances 0.000 claims abstract description 12
- 239000000969 carrier Substances 0.000 claims abstract description 8
- 239000011780 sodium chloride Substances 0.000 claims description 36
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 33
- 239000011701 zinc Substances 0.000 claims description 33
- 229910052725 zinc Inorganic materials 0.000 claims description 33
- 150000003839 salts Chemical class 0.000 claims description 32
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 210000000515 Tooth Anatomy 0.000 claims description 12
- 239000000377 silicon dioxide Substances 0.000 claims description 12
- 239000011230 binding agent Substances 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 11
- 238000004140 cleaning Methods 0.000 claims description 10
- IUTCEZPPWBHGIX-UHFFFAOYSA-N tin(2+) Chemical compound [Sn+2] IUTCEZPPWBHGIX-UHFFFAOYSA-N 0.000 claims description 10
- 239000007844 bleaching agent Substances 0.000 claims description 9
- 230000000111 anti-oxidant Effects 0.000 claims description 8
- 230000002882 anti-plaque Effects 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- UOURRHZRLGCVDA-UHFFFAOYSA-D pentazinc;dicarbonate;hexahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Zn+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2].[O-]C([O-])=O.[O-]C([O-])=O UOURRHZRLGCVDA-UHFFFAOYSA-D 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 229960001927 Cetylpyridinium Chloride Drugs 0.000 claims description 7
- YMKDRGPMQRFJGP-UHFFFAOYSA-M Cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 7
- 229920000388 Polyphosphate Chemical class 0.000 claims description 7
- 239000001205 polyphosphate Chemical class 0.000 claims description 7
- 235000011176 polyphosphates Nutrition 0.000 claims description 7
- KOSIBOSSOGMXIG-UHFFFAOYSA-L zinc;oxido hydrogen carbonate Chemical compound [Zn+2].OC(=O)O[O-].OC(=O)O[O-] KOSIBOSSOGMXIG-UHFFFAOYSA-L 0.000 claims description 7
- CKAPSXZOOQJIBF-UHFFFAOYSA-N Hexachlorobenzene Chemical compound ClC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl CKAPSXZOOQJIBF-UHFFFAOYSA-N 0.000 claims description 6
- 125000000129 anionic group Chemical group 0.000 claims description 6
- 230000000675 anti-caries Effects 0.000 claims description 6
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 6
- 229920001888 polyacrylic acid Polymers 0.000 claims description 6
- 230000002272 anti-calculus Effects 0.000 claims description 5
- 235000015097 nutrients Nutrition 0.000 claims description 5
- XPPKVPWEQAFLFU-UHFFFAOYSA-J Pyrophosphate Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 4
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims description 4
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 claims description 4
- PTFCDOFLOPIGGS-UHFFFAOYSA-N zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 4
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 claims description 3
- 240000008528 Hevea brasiliensis Species 0.000 claims description 3
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 claims description 3
- FKHIFSZMMVMEQY-UHFFFAOYSA-N Talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 239000000391 magnesium silicate Substances 0.000 claims description 3
- 229910052919 magnesium silicate Inorganic materials 0.000 claims description 3
- 235000019792 magnesium silicate Nutrition 0.000 claims description 3
- 229920001194 natural rubber Polymers 0.000 claims description 3
- 230000001698 pyrogenic Effects 0.000 claims description 3
- 229910052604 silicate mineral Inorganic materials 0.000 claims description 3
- 229960003500 triclosan Drugs 0.000 claims description 3
- 229940005553 Analgesics and anesthetics Drugs 0.000 claims description 2
- 230000001680 brushing Effects 0.000 claims description 2
- 229910052615 phyllosilicate Inorganic materials 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 229940091251 Zinc Supplements Drugs 0.000 description 28
- 239000000126 substance Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000008375 oral care agent Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 229910052783 alkali metal Inorganic materials 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 10
- 239000000606 toothpaste Substances 0.000 description 10
- 229910052500 inorganic mineral Inorganic materials 0.000 description 9
- 239000000049 pigment Substances 0.000 description 9
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 9
- 235000010755 mineral Nutrition 0.000 description 8
- 239000011707 mineral Substances 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 6
- ANOBYBYXJXCGBS-UHFFFAOYSA-L Tin(II) fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
- 150000001340 alkali metals Chemical class 0.000 description 6
- 235000015872 dietary supplement Nutrition 0.000 description 6
- LILHXQCLSOZSRO-UHFFFAOYSA-J dizinc;oxozinc;dicarbonate;tetrahydrate Chemical compound O.O.O.O.[Zn+2].[Zn+2].[Zn]=O.[Zn]=O.[Zn]=O.[O-]C([O-])=O.[O-]C([O-])=O LILHXQCLSOZSRO-UHFFFAOYSA-J 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 229920000098 polyolefin Polymers 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000600 sorbitol Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- 239000011667 zinc carbonate Substances 0.000 description 6
- 235000004416 zinc carbonate Nutrition 0.000 description 6
- 229910000010 zinc carbonate Inorganic materials 0.000 description 6
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Diphosphoinositol tetrakisphosphate Chemical compound OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 5
- 229940015001 Glycerin Drugs 0.000 description 5
- 210000000214 Mouth Anatomy 0.000 description 5
- 229960002799 Stannous Fluoride Drugs 0.000 description 5
- 229940034610 Toothpaste Drugs 0.000 description 5
- 229920001525 carrageenan Polymers 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 229960005150 glycerol Drugs 0.000 description 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 5
- 238000000518 rheometry Methods 0.000 description 5
- 239000011775 sodium fluoride Substances 0.000 description 5
- 235000013024 sodium fluoride Nutrition 0.000 description 5
- 229940113118 Carrageenan Drugs 0.000 description 4
- UQEAIHBTYFGYIE-UHFFFAOYSA-N Hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- OSWPMRLSEDHDFF-UHFFFAOYSA-N Methyl salicylate Chemical class COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229940029983 VITAMINS Drugs 0.000 description 4
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 4
- 238000005296 abrasive Methods 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 125000004432 carbon atoms Chemical group C* 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- QBWCMBCROVPCKQ-UHFFFAOYSA-M chlorite Chemical class [O-]Cl=O QBWCMBCROVPCKQ-UHFFFAOYSA-M 0.000 description 4
- 239000007859 condensation product Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229940008099 dimethicone Drugs 0.000 description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000004922 lacquer Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin dichloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229930003231 vitamins Natural products 0.000 description 4
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-Dichlorophenoxyacetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 3
- GPLRAVKSCUXZTP-UHFFFAOYSA-N 3-(2,3-dihydroxypropoxy)propane-1,2-diol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-L CHEBI:8154 Chemical class [O-]P([O-])=O ABLZXFCXXLZCGV-UHFFFAOYSA-L 0.000 description 3
- 208000006558 Dental Calculus Diseases 0.000 description 3
- 210000003298 Dental Enamel Anatomy 0.000 description 3
- 208000007565 Gingivitis Diseases 0.000 description 3
- 241000871495 Heeria argentea Species 0.000 description 3
- AQLJVWUFPCUVLO-UHFFFAOYSA-N Hydrogen peroxide - urea Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 3
- 229960004063 Propylene glycol Drugs 0.000 description 3
- 229940083982 Sodium Phytate Drugs 0.000 description 3
- FQENQNTWSFEDLI-UHFFFAOYSA-J Tetrasodium pyrophosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000001336 alkenes Chemical group 0.000 description 3
- 239000003945 anionic surfactant Substances 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 230000000845 anti-microbial Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000011180 diphosphates Nutrition 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229940094522 laponite Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- HKYXYLUKNVSNLK-UHFFFAOYSA-N (2,3,4,5,6-pentaphosphonooxycyclohexyl) dihydrogen phosphate;tin(2+) Chemical compound [Sn+2].OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O HKYXYLUKNVSNLK-UHFFFAOYSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- YFVBASFBIJFBAI-UHFFFAOYSA-M 1-tetradecylpyridin-1-ium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+]1=CC=CC=C1 YFVBASFBIJFBAI-UHFFFAOYSA-M 0.000 description 2
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical class OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
- ANAAMBRRWOGKGU-UHFFFAOYSA-M 4-ethyl-1-tetradecylpyridin-1-ium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+]1=CC=C(CC)C=C1 ANAAMBRRWOGKGU-UHFFFAOYSA-M 0.000 description 2
- LZNWYQJJBLGYLT-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-ylthieno[2,3-e]thiazine-3-carboxamide Chemical compound OC=1C=2SC=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LZNWYQJJBLGYLT-UHFFFAOYSA-N 0.000 description 2
- 229940022659 Acetaminophen Drugs 0.000 description 2
- 229960005069 Calcium Drugs 0.000 description 2
- LHJQIRIGXXHNLA-UHFFFAOYSA-N Calcium peroxide Chemical compound [Ca+2].[O-][O-] LHJQIRIGXXHNLA-UHFFFAOYSA-N 0.000 description 2
- RECUKUPTGUEGMW-UHFFFAOYSA-N Carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N Catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- OSVXSBDYLRYLIG-UHFFFAOYSA-N Chlorine dioxide Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229940105990 DIGLYCERIN Drugs 0.000 description 2
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Didronel Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N Diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N Dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N Hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 2
- 229960000905 Indomethacin Drugs 0.000 description 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N Ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N Linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- 240000006217 Mentha pulegium Species 0.000 description 2
- 235000016257 Mentha pulegium Nutrition 0.000 description 2
- 229940053207 Niacin Drugs 0.000 description 2
- 210000003300 Oropharynx Anatomy 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M Potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N Potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical compound C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 description 2
- UKLNMMHNWFDKNT-UHFFFAOYSA-M Sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 2
- TWGUZEUZLCYTCG-UHFFFAOYSA-N Sodium fluorosilicate Chemical compound [Na+].[Na+].F[Si-2](F)(F)(F)(F)F TWGUZEUZLCYTCG-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- BFDWBSRJQZPEEB-UHFFFAOYSA-L Sodium monofluorophosphate Chemical compound [Na+].[Na+].[O-]P([O-])(F)=O BFDWBSRJQZPEEB-UHFFFAOYSA-L 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N Sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N Thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 239000005844 Thymol Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Trimethylglycine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229910001515 alkali metal fluoride Inorganic materials 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000202 analgesic Effects 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000003610 anti-gingivitis Effects 0.000 description 2
- 230000000840 anti-viral Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 235000019402 calcium peroxide Nutrition 0.000 description 2
- 229940078916 carbamide peroxide Drugs 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229910001919 chlorite Inorganic materials 0.000 description 2
- 229910052619 chlorite group Inorganic materials 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 235000019820 disodium diphosphate Nutrition 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 150000004673 fluoride salts Chemical class 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229910021485 fumed silica Inorganic materials 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920000591 gum Polymers 0.000 description 2
- WPEXVRDUEAJUGY-UHFFFAOYSA-B hexacalcium;(2,3,4,5,6-pentaphosphonatooxycyclohexyl) phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])(=O)OC1C(OP([O-])([O-])=O)C(OP([O-])([O-])=O)C(OP([O-])([O-])=O)C(OP([O-])([O-])=O)C1OP([O-])([O-])=O WPEXVRDUEAJUGY-UHFFFAOYSA-B 0.000 description 2
- 229940005740 hexametaphosphate Drugs 0.000 description 2
- 235000001050 hortel pimenta Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960004752 ketorolac Drugs 0.000 description 2
- 239000003912 lipotropic agent Substances 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229960001047 methyl salicylate Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 235000006678 peppermint Nutrition 0.000 description 2
- 235000015132 peppermint Nutrition 0.000 description 2
- 235000007735 peppermint Nutrition 0.000 description 2
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000001953 sensory Effects 0.000 description 2
- 229960002218 sodium chlorite Drugs 0.000 description 2
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 2
- 235000019832 sodium triphosphate Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 239000001119 stannous chloride Substances 0.000 description 2
- 229940013123 stannous chloride Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 2
- 229930007823 thymol Natural products 0.000 description 2
- 229960000790 thymol Drugs 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N α-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- DIYWRNLYKJKHAM-MDOVXXIYSA-N (-)-cubebin Chemical compound C1=C2OCOC2=CC(C[C@@H]2[C@@H](CC=3C=C4OCOC4=CC=3)CO[C@@H]2O)=C1 DIYWRNLYKJKHAM-MDOVXXIYSA-N 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N (1S,3R,4E,6E,8E,10E,14E,16E,18S,19R,20R,21S,25R,27R,29R,32R,33R,35S,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14, Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- GDRWQOJIKFWLOC-UHFFFAOYSA-N (2-phosphonopyrrolidin-2-yl)phosphonic acid Chemical compound OP(O)(=O)C1(P(O)(O)=O)CCCN1 GDRWQOJIKFWLOC-UHFFFAOYSA-N 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N (2R,3R,4S)-4-[(diaminomethylidene)amino]-3-acetamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- CKUJRAYMVVJDMG-IYEMJOQQSA-L (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate;tin(2+) Chemical compound [Sn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O CKUJRAYMVVJDMG-IYEMJOQQSA-L 0.000 description 1
- QJVHTELASVOWBE-AGNWQMPPSA-N (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 QJVHTELASVOWBE-AGNWQMPPSA-N 0.000 description 1
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3S,3aR,6R,6aR)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
- UESHVCAYLZYGOX-FFHNEAJVSA-N (4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;2-acetyloxybenzoic acid Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC UESHVCAYLZYGOX-FFHNEAJVSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- VJGGHXVGBSZVMZ-QIZQQNKQSA-N (Z)-7-[(1R,2R,3R,5S)-2-[(E,3R)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoic acid Chemical class C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(Cl)=C1 VJGGHXVGBSZVMZ-QIZQQNKQSA-N 0.000 description 1
- JLPAMKUIIFHLBH-UHFFFAOYSA-M 1,2-dihydroxypropane-1-sulfonate Chemical compound CC(O)C(O)S([O-])(=O)=O JLPAMKUIIFHLBH-UHFFFAOYSA-M 0.000 description 1
- OQBLGYCUQGDOOR-UHFFFAOYSA-L 1,3,2$l^{2}-dioxastannolane-4,5-dione Chemical compound O=C1O[Sn]OC1=O OQBLGYCUQGDOOR-UHFFFAOYSA-L 0.000 description 1
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N 1,8-cineol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- GPXCJKUXBIGASD-UHFFFAOYSA-N 1-phosphonobutane-1,2,4-tricarboxylic acid Chemical compound OC(=O)CCC(C(O)=O)C(C(O)=O)P(O)(O)=O GPXCJKUXBIGASD-UHFFFAOYSA-N 0.000 description 1
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical class C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
- RPZANUYHRMRTTE-UHFFFAOYSA-N 2,3,4-trimethoxy-6-(methoxymethyl)-5-[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[3,4,5-tris(2-hydroxybutoxy)-6-[4,5,6-tris(2-hydroxybutoxy)-2-(2-hydroxybutoxymethyl)oxan-3-yl]oxyoxan-2-yl]methoxy]butan-2-ol Chemical compound COC1C(OC)C(OC)C(COC)OC1OC1C(OC)C(OC)C(OC)OC1COC.CCC(O)COC1C(OCC(O)CC)C(OCC(O)CC)C(COCC(O)CC)OC1OC1C(OCC(O)CC)C(OCC(O)CC)C(OCC(O)CC)OC1COCC(O)CC RPZANUYHRMRTTE-UHFFFAOYSA-N 0.000 description 1
- SZGVJLCXTSBVKL-UHFFFAOYSA-H 2,4,6,8,10,12-hexaoxido-1,3,5,7,9,11-hexaoxa-2$l^{5},4$l^{5},6$l^{5},8$l^{5},10$l^{5},12$l^{5}-hexaphosphacyclododecane 2,4,6,8,10,12-hexaoxide Chemical compound [O-]P1(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])(=O)O1 SZGVJLCXTSBVKL-UHFFFAOYSA-H 0.000 description 1
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-Methyl-2,4-pentanediol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 1
- QSFOWAYMMZCQNF-UHFFFAOYSA-N 2-[3-(4-propylheptyl)morpholin-4-yl]ethanol Chemical compound CCCC(CCC)CCCC1COCCN1CCO QSFOWAYMMZCQNF-UHFFFAOYSA-N 0.000 description 1
- RWMSXNCJNSILON-UHFFFAOYSA-N 2-[4-(2-propylpentyl)piperidin-1-yl]ethanol Chemical compound CCCC(CCC)CC1CCN(CCO)CC1 RWMSXNCJNSILON-UHFFFAOYSA-N 0.000 description 1
- KOYYEPZTIWTHDY-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;zinc;dihydrate Chemical compound O.O.[Zn].[Zn].[Zn].OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O KOYYEPZTIWTHDY-UHFFFAOYSA-N 0.000 description 1
- UDFNOXIWFOPREQ-UHFFFAOYSA-N 2-phosphonopropane-1,1,1-tricarboxylic acid Chemical compound OP(=O)(O)C(C)C(C(O)=O)(C(O)=O)C(O)=O UDFNOXIWFOPREQ-UHFFFAOYSA-N 0.000 description 1
- AGGIJOLULBJGTQ-UHFFFAOYSA-M 2-sulfoacetate Chemical class OC(=O)CS([O-])(=O)=O AGGIJOLULBJGTQ-UHFFFAOYSA-M 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-Aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- FHEHIXJLCWUPCZ-UHFFFAOYSA-N 4-prop-2-enylbenzene-1,2-diol Chemical compound OC1=CC=C(CC=C)C=C1O FHEHIXJLCWUPCZ-UHFFFAOYSA-N 0.000 description 1
- YXTDAZMTQFUZHK-UHFFFAOYSA-L 5,6-dihydroxy-1,3,2$l^{2}-dioxastannepane-4,7-dione Chemical compound [Sn+2].[O-]C(=O)C(O)C(O)C([O-])=O YXTDAZMTQFUZHK-UHFFFAOYSA-L 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N 8-Hydroxyquinoline Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 1
- OIRDTQYFTABQOQ-GAWUUDPSSA-N 9-β-D-XYLOFURANOSYL-ADENINE Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O OIRDTQYFTABQOQ-GAWUUDPSSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N AI2O3 Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229940035676 ANALGESICS Drugs 0.000 description 1
- FZERHIULMFGESH-UHFFFAOYSA-N Acetanilide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 229940023040 Acyclovir Drugs 0.000 description 1
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 description 1
- LFVVNPBBFUSSHL-UHFFFAOYSA-N Alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 description 1
- 229940045714 Alkyl sulfonate alkylating agents Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 229940098164 Augmentin Drugs 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N Benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 229960005274 Benzocaine Drugs 0.000 description 1
- 229940083828 Bioflavonoid drugs for capillary stabilizing Drugs 0.000 description 1
- 229940093797 Bioflavonoids Drugs 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- 239000004343 Calcium peroxide Substances 0.000 description 1
- 229960001631 Carbomer Drugs 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229940085262 Cetyl dimethicone Drugs 0.000 description 1
- 229960003260 Chlorhexidine Drugs 0.000 description 1
- 239000004155 Chlorine dioxide Substances 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- QDOXWKRWXJOMAK-UHFFFAOYSA-N Chromium(III) oxide Chemical compound O=[Cr]O[Cr]=O QDOXWKRWXJOMAK-UHFFFAOYSA-N 0.000 description 1
- 229960000724 Cidofovir Drugs 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovirum Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 235000004310 Cinnamomum zeylanicum Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 240000002268 Citrus limon Species 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N Clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N Clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 239000005749 Copper compound Substances 0.000 description 1
- 239000005750 Copper hydroxide Substances 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L Copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- GWFAVIIMQDUCRA-UHFFFAOYSA-L Copper(II) fluoride Chemical compound [F-].[F-].[Cu+2] GWFAVIIMQDUCRA-UHFFFAOYSA-L 0.000 description 1
- JJLJMEJHUUYSSY-UHFFFAOYSA-L Copper(II) hydroxide Chemical compound [OH-].[OH-].[Cu+2] JJLJMEJHUUYSSY-UHFFFAOYSA-L 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L Copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 1
- 229960001334 Corticosteroids Drugs 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-XVFCMESISA-N Cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-XVFCMESISA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940038485 DISODIUM PYROPHOSPHATE Drugs 0.000 description 1
- 229960003854 Delmopinol Drugs 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N Diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L Dipotassium phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- GYQBBRRVRKFJRG-UHFFFAOYSA-L Disodium pyrophosphate Chemical compound [Na+].[Na+].OP([O-])(=O)OP(O)([O-])=O GYQBBRRVRKFJRG-UHFFFAOYSA-L 0.000 description 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N Docosahexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 1
- 229960001859 Domiphen bromide Drugs 0.000 description 1
- OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 description 1
- 229960003722 Doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N Doxycycline Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 229960005135 Eicosapentaenoic Acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N Eicosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229960005293 Etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N Etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229940109501 Eucalyptol Drugs 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 235000010705 Eucalyptus maculata Nutrition 0.000 description 1
- 235000009683 Eucalyptus polybractea Nutrition 0.000 description 1
- 235000009687 Eucalyptus sargentii Nutrition 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Exidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- RDJGLLICXDHJDY-UHFFFAOYSA-N Fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 1
- 229960001419 Fenoprofen Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N Fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 Fentanyl Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N Flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960000304 Folic Acid Drugs 0.000 description 1
- ZJAOAACCNHFJAH-UHFFFAOYSA-N Foscarnet Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 1
- 229940065115 GRAPEFRUIT EXTRACT Drugs 0.000 description 1
- 229960002963 Ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N Ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- NYHBQMYGNKIUIF-PXMDKTAGSA-N Guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1O[C@@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-PXMDKTAGSA-N 0.000 description 1
- 229940029575 Guanosine Drugs 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 229940093912 Gynecological Sulfonamides Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- FUWUEFKEXZQKKA-UHFFFAOYSA-N Hinokitiol Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N Hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 229960004716 Idoxuridine Drugs 0.000 description 1
- 108090000745 Immune Sera Proteins 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229960000367 Inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N Inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 240000000661 Kaempferia galanga Species 0.000 description 1
- 235000013421 Kaempferia galanga Nutrition 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 229940001447 Lactate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 229960004488 Linolenic Acid Drugs 0.000 description 1
- 229940040504 Lipotropic Agents Drugs 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- SPAGIJMPHSUYSE-UHFFFAOYSA-N Magnesium peroxide Chemical compound [Mg+2].[O-][O-] SPAGIJMPHSUYSE-UHFFFAOYSA-N 0.000 description 1
- 229940013798 Meclofenamate Drugs 0.000 description 1
- 229940057917 Medium chain triglycerides Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N Mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960003987 Melatonin Drugs 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 229960004452 Methionine Drugs 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N Methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 229960000282 Metronidazole Drugs 0.000 description 1
- 229960004023 Minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N Minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229940045641 Monobasic Sodium Phosphate Drugs 0.000 description 1
- ZVXNYZWXUADSRV-UHFFFAOYSA-N N-octyl-1-[10-(4-octyliminopyridin-1-yl)decyl]pyridin-4-imine Chemical compound C1=CC(=NCCCCCCCC)C=CN1CCCCCCCCCCN1C=CC(=NCCCCCCCC)C=C1 ZVXNYZWXUADSRV-UHFFFAOYSA-N 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N Nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- 229960000805 Nalbuphine Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960001774 OCTENIDINE Drugs 0.000 description 1
- 244000227633 Ocotea pretiosa Species 0.000 description 1
- 235000004263 Ocotea pretiosa Nutrition 0.000 description 1
- 229950002404 Octapinol Drugs 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 235000006297 Origanum majorana Nutrition 0.000 description 1
- 229960002194 Oseltamivir phosphate Drugs 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- 229940116985 POTASSIUM LAURYL SULFATE Drugs 0.000 description 1
- XCOJIVIDDFTHGB-UEUZTHOGSA-N Perillartine Chemical compound CC(=C)[C@H]1CCC(\C=N\O)=CC1 XCOJIVIDDFTHGB-UEUZTHOGSA-N 0.000 description 1
- UUZZMWZGAZGXSF-UHFFFAOYSA-N Peroxynitric acid Chemical compound OON(=O)=O UUZZMWZGAZGXSF-UHFFFAOYSA-N 0.000 description 1
- 229960003893 Phenacetin Drugs 0.000 description 1
- CPJSUEIXXCENMM-UHFFFAOYSA-N Phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 1
- 229960000897 Phenazocine Drugs 0.000 description 1
- ZQHYKVKNPWDQSL-KNXBSLHKSA-N Phenazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CCC1=CC=CC=C1 ZQHYKVKNPWDQSL-KNXBSLHKSA-N 0.000 description 1
- 229960002895 Phenylbutazone Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- ONQDVAFWWYYXHM-UHFFFAOYSA-M Potassium lauryl sulfate Chemical compound [K+].CCCCCCCCCCCCOS([O-])(=O)=O ONQDVAFWWYYXHM-UHFFFAOYSA-M 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- ODUOJXZPIYUATO-UHFFFAOYSA-N Racecadotril Chemical compound C=1C=CC=CC=1COC(=O)CNC(=O)C(CSC(=O)C)CC1=CC=CC=C1 ODUOJXZPIYUATO-UHFFFAOYSA-N 0.000 description 1
- 229960000329 Ribavirin Drugs 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 229960002477 Riboflavin Drugs 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- AUNGANRZJHBGPY-OUCADQQQSA-N Riboflavin Natural products OC[C@@H](O)[C@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-OUCADQQQSA-N 0.000 description 1
- 229960004376 Rimantadine Hydrochloride Drugs 0.000 description 1
- OZBDFBJXRJWNAV-UHFFFAOYSA-N Rimantadine hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(C(N)C)C3 OZBDFBJXRJWNAV-UHFFFAOYSA-N 0.000 description 1
- 229940007163 STANNOUS TARTRATE Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940085605 Saccharin Sodium Drugs 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- WKEDVNSFRWHDNR-UHFFFAOYSA-N Salicylanilide Chemical compound OC1=CC=CC=C1C(=O)NC1=CC=CC=C1 WKEDVNSFRWHDNR-UHFFFAOYSA-N 0.000 description 1
- 235000002912 Salvia officinalis Nutrition 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 229960001462 Sodium Cyclamate Drugs 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Sodium cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H Sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- MWNQXXOSWHCCOZ-UHFFFAOYSA-M Sodium percarbonate Chemical group [Na+].OOC([O-])=O MWNQXXOSWHCCOZ-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- NYKCGQQJNVPOLU-ONTIZHBOSA-N Spiradoline Chemical compound C([C@@H]([C@H](C1)N2CCCC2)N(C)C(=O)CC=2C=C(Cl)C(Cl)=CC=2)C[C@]21CCCO2 NYKCGQQJNVPOLU-ONTIZHBOSA-N 0.000 description 1
- 229950006495 Spiradoline Drugs 0.000 description 1
- 206010041857 Squamous cell carcinoma of the oral cavity Diseases 0.000 description 1
- RCIVOBGSMSSVTR-UHFFFAOYSA-L Stannous sulfate Chemical compound [SnH2+2].[O-]S([O-])(=O)=O RCIVOBGSMSSVTR-UHFFFAOYSA-L 0.000 description 1
- AHBGXTDRMVNFER-UHFFFAOYSA-L Strontium chloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 1
- UHCGLDSRFKGERO-UHFFFAOYSA-N Strontium peroxide Chemical compound [Sr+2].[O-][O-] UHCGLDSRFKGERO-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N Sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 Sulindac Drugs 0.000 description 1
- 240000005147 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- VOKSWYLNZZRQPF-UHFFFAOYSA-N Talwin Chemical compound C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-UHFFFAOYSA-N 0.000 description 1
- 229960002180 Tetracycline Drugs 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- FQXXSQDCDRQNQE-VMDGZTHMSA-N Thebaine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(OC)C5=C4[C@@]21[C@H]3O5 FQXXSQDCDRQNQE-VMDGZTHMSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229940104230 Thymidine Drugs 0.000 description 1
- ZSUXOVNWDZTCFN-UHFFFAOYSA-L Tin(II) bromide Chemical compound Br[Sn]Br ZSUXOVNWDZTCFN-UHFFFAOYSA-L 0.000 description 1
- JTDNNCYXCFHBGG-UHFFFAOYSA-L Tin(II) iodide Chemical compound I[Sn]I JTDNNCYXCFHBGG-UHFFFAOYSA-L 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N Tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229940095688 Toothpaste Product Drugs 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 229960003962 Trifluridine Drugs 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N Trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Trioxopurine Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- UEVAMYPIMMOEFW-UHFFFAOYSA-N Trolamine salicylate Chemical compound OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O UEVAMYPIMMOEFW-UHFFFAOYSA-N 0.000 description 1
- 229960004799 Tryptophan Drugs 0.000 description 1
- 229940116269 Uric Acid Drugs 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclover Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 229940045997 Vitamin A Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229940046009 Vitamin E Drugs 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 Xylitol Drugs 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229940068475 ZINC CITRATE Drugs 0.000 description 1
- 229940050168 ZINC LACTATE Drugs 0.000 description 1
- 229960001028 Zanamivir Drugs 0.000 description 1
- 229940085658 Zinc Citrate Trihydrate Drugs 0.000 description 1
- 229960001296 Zinc Oxide Drugs 0.000 description 1
- 229940105296 Zinc Peroxide Drugs 0.000 description 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L Zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- WOHVONCNVLIHKY-UHFFFAOYSA-L [Ba+2].[O-]Cl=O.[O-]Cl=O Chemical compound [Ba+2].[O-]Cl=O.[O-]Cl=O WOHVONCNVLIHKY-UHFFFAOYSA-L 0.000 description 1
- OYKMTVCLSAYRGV-UHFFFAOYSA-J [Na+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O Chemical class [Na+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O OYKMTVCLSAYRGV-UHFFFAOYSA-J 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- DTHZWUDUWBPDQI-UHFFFAOYSA-N [Zn].ClO Chemical compound [Zn].ClO DTHZWUDUWBPDQI-UHFFFAOYSA-N 0.000 description 1
- 229960001413 acetanilide Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N acyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229950010221 alexidine Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000004973 alkali metal peroxides Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000004974 alkaline earth metal peroxides Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000003444 anaesthetic Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agents Drugs 0.000 description 1
- 229940111136 antiinflammatory and antirheumatic drugs Fenamates Drugs 0.000 description 1
- 229940045686 antimetabolites antineoplastic Purine analogs Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 150000004287 bisbiguanides Chemical class 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- RMRJXGBAOAMLHD-CTAPUXPBSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-CTAPUXPBSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- QXIKMJLSPJFYOI-UHFFFAOYSA-L calcium;dichlorite Chemical compound [Ca+2].[O-]Cl=O.[O-]Cl=O QXIKMJLSPJFYOI-UHFFFAOYSA-L 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960000539 carbamide Drugs 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- 239000004464 cereal grain Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000005285 chemical preparation method Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 235000019398 chlorine dioxide Nutrition 0.000 description 1
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229930007907 citral Natural products 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 150000001880 copper compounds Chemical class 0.000 description 1
- 229910001956 copper hydroxide Inorganic materials 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- RFKZUAOAYVHBOY-UHFFFAOYSA-M copper(1+);acetate Chemical compound [Cu+].CC([O-])=O RFKZUAOAYVHBOY-UHFFFAOYSA-M 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000030810 detection of chemical stimulus involved in sensory perception of taste Effects 0.000 description 1
- PNOXNTGLSKTMQO-UHFFFAOYSA-L diacetyloxytin Chemical compound CC(=O)O[Sn]OC(C)=O PNOXNTGLSKTMQO-UHFFFAOYSA-L 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- CQAIPTBBCVQRMD-UHFFFAOYSA-L dipotassium;phosphono phosphate Chemical compound [K+].[K+].OP(O)(=O)OP([O-])([O-])=O CQAIPTBBCVQRMD-UHFFFAOYSA-L 0.000 description 1
- 229940042396 direct acting antivirals Thiosemicarbazones Drugs 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960004363 doconexent Drugs 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- PTNGTIMIEJADLN-UHFFFAOYSA-N ethene;2-hydroxyacetic acid Chemical compound C=C.OCC(O)=O PTNGTIMIEJADLN-UHFFFAOYSA-N 0.000 description 1
- 235000001612 eucalyptus Nutrition 0.000 description 1
- 235000001617 eucalyptus Nutrition 0.000 description 1
- 235000001621 eucalyptus Nutrition 0.000 description 1
- 235000006356 eucalyptus Nutrition 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 150000002193 fatty amides Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229930003935 flavonoids Natural products 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229930008393 geraniol Natural products 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- WYGJAFDJPBTRSB-UHFFFAOYSA-B hexazinc;(2,3,4,5,6-pentaphosphonatooxycyclohexyl) phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2].[O-]P([O-])(=O)OC1C(OP([O-])([O-])=O)C(OP([O-])([O-])=O)C(OP([O-])([O-])=O)C(OP([O-])([O-])=O)C1OP([O-])([O-])=O WYGJAFDJPBTRSB-UHFFFAOYSA-B 0.000 description 1
- 229960004867 hexetidine Drugs 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- DLINORNFHVEIFE-UHFFFAOYSA-N hydrogen peroxide;zinc Chemical compound [Zn].OO DLINORNFHVEIFE-UHFFFAOYSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910001506 inorganic fluoride Inorganic materials 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 229940079867 intestinal antiinfectives Sulfonamides Drugs 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229910000460 iron oxide Inorganic materials 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 229960004232 linoleic acid Drugs 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 230000003212 lipotrophic Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- KAGBQTDQNWOCND-UHFFFAOYSA-M lithium;chlorite Chemical compound [Li+].[O-]Cl=O KAGBQTDQNWOCND-UHFFFAOYSA-M 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229960004995 magnesium peroxide Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- IWEDUKDKQUXPLH-UHFFFAOYSA-L magnesium;(2,3,4,5,6-pentaphosphonooxycyclohexyl) phosphate Chemical compound [Mg+2].OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP([O-])([O-])=O)C(OP(O)(O)=O)C1OP(O)(O)=O IWEDUKDKQUXPLH-UHFFFAOYSA-L 0.000 description 1
- NWAPVVCSZCCZCU-UHFFFAOYSA-L magnesium;dichlorite Chemical compound [Mg+2].[O-]Cl=O.[O-]Cl=O NWAPVVCSZCCZCU-UHFFFAOYSA-L 0.000 description 1
- INWUJAAIUAAHJA-UHFFFAOYSA-N magnesium;hexafluorosilicon(2-) Chemical compound [Mg+2].F[Si-2](F)(F)(F)(F)F INWUJAAIUAAHJA-UHFFFAOYSA-N 0.000 description 1
- YRZGPQDNADQQOW-UHFFFAOYSA-L magnesium;potassium;phthalate Chemical compound [Mg+2].[K+].[O-]C(=O)C1=CC=CC=C1C([O-])=O YRZGPQDNADQQOW-UHFFFAOYSA-L 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-M meclofenamic acid(1-) Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C([O-])=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-M 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N nabumeton Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- WTEVQBCEXWBHNA-YFHOEESVSA-N neral Chemical compound CC(C)=CCC\C(C)=C/C=O WTEVQBCEXWBHNA-YFHOEESVSA-N 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 229940005938 ophthalmologic antiinfectives Sulfonamides Drugs 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 239000001048 orange dye Substances 0.000 description 1
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920003366 poly(p-phenylene terephthalamide) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- VISKNDGJUCDNMS-UHFFFAOYSA-M potassium;chlorite Chemical class [K+].[O-]Cl=O VISKNDGJUCDNMS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 150000004672 propanoic acids Chemical class 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229960002862 pyridoxine Drugs 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 230000000306 recurrent Effects 0.000 description 1
- 235000005227 red mallee Nutrition 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229950000975 salicylanilide Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 239000001296 salvia officinalis l. Substances 0.000 description 1
- 229940084560 sanguinarine Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 229940045872 sodium percarbonate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- MWNQXXOSWHCCOZ-UHFFFAOYSA-L sodium;oxido carbonate Chemical compound [Na+].[O-]OC([O-])=O MWNQXXOSWHCCOZ-UHFFFAOYSA-L 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000004215 spores Anatomy 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229940108184 stannous iodide Drugs 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229940013553 strontium chloride Drugs 0.000 description 1
- 229910001631 strontium chloride Inorganic materials 0.000 description 1
- 159000000008 strontium salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 235000019529 tetraterpenoid Nutrition 0.000 description 1
- 229930003945 thebaine Natural products 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 150000003584 thiosemicarbazones Chemical class 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 239000010678 thyme oil Substances 0.000 description 1
- 229910000375 tin(II) sulfate Inorganic materials 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- 229940026752 topical Sulfonamides Drugs 0.000 description 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- MLIKYFGFHUYZAL-UHFFFAOYSA-K trisodium;hydron;phosphonato phosphate Chemical compound [Na+].[Na+].[Na+].OP([O-])(=O)OP([O-])([O-])=O MLIKYFGFHUYZAL-UHFFFAOYSA-K 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- VSJRDSLPNMGNFG-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate;trihydrate Chemical compound O.O.O.[Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O VSJRDSLPNMGNFG-UHFFFAOYSA-H 0.000 description 1
- 229940030300 trolamine salicylate Drugs 0.000 description 1
- 235000013799 ultramarine blue Nutrition 0.000 description 1
- 229960001234 valaciclovir Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000002087 whitening Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 239000011576 zinc lactate Substances 0.000 description 1
- 235000000193 zinc lactate Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- GLZPCOQZEFWAFX-JXMROGBWSA-N β-Geraniol Chemical compound CC(C)=CCC\C(C)=C\CO GLZPCOQZEFWAFX-JXMROGBWSA-N 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Abstract
A dentifrice composition comprising, (a) a hydrophilic clay material, (b) a phytic acid compound, (c) an effective amount of an oral care active, and (d) a polar solvent carrier;wherein the composition is substantially free of abrasive material.
Description
DENTÍFRICA COMPOSITION FREE OF ABRASIVE MATERIAL
FIELD OF THE INVENTION
The present invention relates to a dentifrice composition practically free of abrasive material, and which can still maintain the cleaning benefits of a regular toothpaste.
BACKGROUND OF THE INVENTION
Toothpaste compositions such as toothpastes are routinely used by consumers as part of their oral care hygiene regimes. It is well known that oral care products can offer therapeutic and cosmetic hygiene benefits to consumers. Therapeutic benefits include, but are not limited to, caries prevention, gingivitis prevention, and hypersensitivity control. Cosmetic benefits include, but are not limited to, dental plaque control and tartar formation, removal and prevention of dental stains, tooth whitening, breath freshening, and aesthetic mouth feel characteristics such as sensation of freshness or slippery sensory touch. The use of abrasive material, such as silica, has been considered critical for a long time to provide the aforementioned therapeutic and cosmetic benefits. Abrasive materials provide abrasion
between the toothbrush and the teeth to clean the plaque, spots, and tartar, while also building rheology and structure of the toothpaste to maintain the thermal stability of the total formulation. At the same time, however, the use of abrasive materials can also have certain negative effects on the total formulation. For example, the cost of silica itself is expensive. In addition, the silica adsorbs components in a typical dentifrice composition such as active agents, flavors, and foaming agents, and thus the concentrations of these components must be adjusted in accordance with the predicted loss by the silica. Still further, certain active agents, such as cetylpyridinium chloride, have poor compatibility with silica, and therefore can not be included in a dentifrice composition, despite their known efficacy. In another aspect, the general consumer has the idea that abrasive materials can erode the enamel, if the teeth are brushed very intensively. Based on the foregoing, there is a need for an abrasive-free dentifrice composition, which can still provide the benefits of a regular dentifrice composition. Specifically, there is a need for an abrasive-free dentifrice composition that is thermally stable, and that can provide the same cleaning benefits as abrasive compositions on the market.
BRIEF DESCRIPTION OF THE INVENTION
The present invention is directed to a dentifrice composition comprising: (a) a hydrophilic clay material; (b) a phytic acid compound; (c) an effective amount of an oral care asset; and (d) a polar solvent carrier; wherein the composition is practically free of abrasive material. The present invention is further directed to a method for cleaning teeth without an abrasive. These and other features, aspects, and advantages of the present invention will become apparent to those experienced in the industry, from reading the present disclosure with the accompanying claims.
DETAILED DESCRIPTION OF THE INVENTION
The following is a list of definitions for the terms used herein. "Understand" means that you can add other steps and other ingredients that do not affect the final result. This term includes the expressions "consists of" and "consists essentially of". Unless specifically expressed in any other way, all percentages are by weight of the total composition. All references cited are incorporated herein in their entirety as a reference. The citation of any reference does not imply admitting the possibility of being considered as an industry precedent to the invention claimed. All proportions are proportions by weight, unless specifically indicated otherwise. The present invention is described in detail below, in its aspects of product and process. a) Hydrophilic clay material The composition of the present invention comprises a hydrophilic clay material which swells or thickens in the presence of a polar solvent, and acts as a binder for the dentifrice composition. The hydrophilic clay material may be any known material that is safe and aesthetically acceptable for use in oral care. The hydrophilic clay material provides
a suitable rheology for the present dentifrice composition of various product forms, including liquids, gels, and toothpastes for brushing, which have a viscosity of about 1 mPa.s to about 450,000 Pa.s, as measured with a Brookfield viscometer with a TE spindle. In a highly preferred embodiment, the present dentifrice composition is a gel or toothpaste with suitable body and viscosity, the viscosity being from about 10,000 Pa.s to about 450,000 Pa.s, preferably from about 10,000 Pa.s to about 250,000 Pa.s. Additional binders may be added to provide adequate rheology, as discussed below. Surprisingly, it has been discovered that the hydrophilic clay material provides the aforementioned suitable stability at relatively low levels, and at a relatively low cost, without the existence of an abrasive material in the composition. The hydrophilic clay material is preferably included, by weight of the total composition, from about 0.01% to about 10%, preferably from about 1% to about 5%. Hydrophilic clay materials useful herein include natural and synthesized stratified silicate minerals, pyrogenic silicas, precipitated thickening silica, and mixtures thereof. Stratified silicate minerals may be of natural origin, or synthesized to have magnesium substituted by certain portions of the mineral. Pyrogenic silicas are those that provide very little or no abrasive function and
they have a particle size of less than about 5 μm, typically from about 1 nm to about 1 μm. Precipitated thickening silicas are those that have a degree of aggregation (DOA) of at least about 150 mL / 100 g, preferably at least about 250 mU100 g, and have a particle size of about 1 μm to approximately 50 μm. The precipitated thickening silica can be distinguished from the abrasive silica material, due to its high oil absorption capacity, as defined by the differential optical absorption value (DOA). This capacity provides the property of thickening. Hydrophilic clay materials useful herein and commercially available include the layered magnesium silicate with the trade name LAPONITE series available from Rockwood Additives Limited & Southern Clay Company, pyrogenic silica with an average particle size of about 12 nm under the trade name AEROSOL series and CAB-O-SIL available from Cabot & Degussa Corporation, the amorphous silica precipitated under the tradename ZEODENT 165 from J. M. Huber Company and SYLOX 15 from Grace Davision, and the silica precipitated under the tradename TIXOSIL from Rhodia. b) Phytic Acid Compound The composition of the present invention comprises a phytic acid compound in an amount that provides effective cleaning of the teeth. Phytic acid, also known as myo-inositol
Hexaphosphate, or inositolhexaphosphoric acid, is a natural biodegradable chelating agent of vegetable base in liquid form with chelating performance comparable to ethylenediaminetetraacetic acid (EDTA). The origin of the plants from which the phytic acid compounds can be found, include cereal grains, legumes, nut oilseeds, pollen, spores, and organic soils. The phytic acid compound herein may be the phytic acid itself or its orally acceptable salts including, but not limited to, the alkali metal salts and alkaline earth metal salts. Useful phytic acid salts include sodium phytate, potassium phytate, magnesium phytate, calcium phytate, stannous phytate, zinc phytate, copper phytate, ferric phytate, and mixtures thereof. Surprisingly, it has been found that the phytic acid compound provides a good cleaning effect in the present abrasive-free composition without stains that can be perceived by the consumer, and is compatible with the present polar solvent carrier, as well as a wide variety of ingredients oral care assets. Without being limited by theory, it is believed that the phytic acid compound provides an exclusive good cleaning due to its liquid form, when flowing between the teeth. It is believed that this flow provides cleaning differently from solid abrasive materials. In addition, it is believed that the phytic acid compound provides a positive effect to protect tooth enamel from dissolution by acid, and anti-jar effect. Commercially available phytic acid compounds useful herein include phytic acid solution, sodium phytate, phytate
magnesium, calcium phytate, and stannous phytate available from Sichuan Chengdu Yason, Shikishima Starch Manufacturing Company, and Nibbio. c) Oral Care Active The composition of the present invention comprises an oral care active that provides the intended therapeutic oral care benefit. Oral care assets useful herein include anticalculus agents, stannous ion sources, fluoride ion sources, bleaching agents, antimicrobial agents, antiplaque agents, anti-inflammatory agents, nutrients, antioxidants, antiviral agents, analgesics and anesthetics, stratified material containing zinc, and mixtures of these. c-1) Anticalculus Agent Oral care agents useful herein include an anticalculus agent, which in one embodiment may be present from about 0.05% to about 50%, by weight of the composition for oral care, in another embodiment is from about 0.05% to about 25%. The anticalculus agent can be selected from the group consisting of polyphosphates (including pyrophosphates) and the salts thereof; polyaminopropanesulfonic acid (AMPS) and salts thereof; polyolefin sulfonates and the salts thereof; polyvinyl phosphates and the salts thereof; polyolefin phosphates and the salts thereof; diphosphonates and the salts thereof; phosphonoalkanecarboxylic acid and the salts thereof; polyphosphonates and the salts thereof; polyvinyl phosphonates and salts thereof; polyolefin phosphonates and salts thereof; polypeptides; and mixtures of these. In one embodiment, the salts are salts
of alkali metals. Polyphosphates are generally used as the fully or partially neutralized salts of water-soluble alkali metals such as the potassium, sodium, ammonium salts, and mixtures thereof. Inorganic polyphosphate salts include tripolyphosphate, tetrapolyphosphate of alkali metals (eg, sodium), potassium hydrogen phosphate, sodium hydrogen phosphate, dialkali metal diacid (eg, disodium), monoacid of trialkaline metals (p. eg, trisodium), alkali metal hexametaphosphate (eg, sodium), and mixtures thereof. Polyphosphates greater than tetrapolyphosphate usually occur as amorphous vitreous materials. In one embodiment, the polyphosphates are those manufactured by FMC Corporation, commercially known as Sodafos (n = 6), Hexaphos (n = 13) and Glass H (n = 21, sodium hexametaphosphate), and mixtures thereof. Pyrophosphate salts useful in the present invention include alkali metal pyrophosphates, mono, di, and tripotassium sodium pyrophosphates, double alkali metal pyrophosphates, tetrametal alkaline pyrophosphate salts, and mixtures thereof. In one embodiment, the pyrophosphate salt is selected from the group comprising trisodium pyrophosphate, diacid disodium pyrophosphate (Na2H2P2O7), dipotassium pyrophosphate, tetrasodium pyrophosphate (Na4P2?), Tetrapotassium pyrophosphate (K P2? 7), and mixtures thereof. Polyolefin sulfonates include those in which the olefin group contains 2 or more carbon atoms, and salts thereof. Polyolefin phosphonates include those wherein the olefin group contains 2 or more carbon atoms. The polyvinylphosphonates include polyvinylphosphonic acid. Diphosphonates and their salts include azocycloalkan-2,2-diphosphonic acids and their salts, acid ions
azocycloalkan-2,2-diphosphonates and their salts, azacyclohexane-2,2-diphosphonic acid, azacyclopentane-2,2-diphosphonic acid, N-methyl-azacyclopentane-2,3-diphosphonic acid, EHDP (ethane-1-hydroxy acid) -1, 1, -diphosphonic acid), AHP (azacycloheptan-2,2-diphosphonic acid), ethan-1-amino-1,1-diphosphonate, dichloromethane diphosphonate, etc. The phosphonoalkanecarboxylic acid or its alkali metal salts include PPTA (phosphonopropanetricarboxylic acid), PBTA (phosphonobutane-1, 2,4-tricarboxylic acid), each as acid or alkali metal salts. Polyolefin phosphates include those wherein the olefin group contains 2 or more carbon atoms. Other useful materials include synthetic anionic polymers, including polyacrylates and copolymers of anhydride or maleic acid and methyl vinyl ether (eg, Gantrez), as described, for example, in U.S. Pat. no. 4,627,977, as well as, for example, polyaminopropanesulfonic acid (AMPS), zinc citrate trihydrate, polyphosphates (e.g., tripolyphosphate); hexametaphosphate), diphosphonates (e.g., EHDP; AHP), polypeptides (such as polyaspartic and polyglutamic acids), and mixtures thereof. In addition, the oral care composition may include a polymeric carrier, such as those described in U.S. Pat. num. 6,682,722 and 6,589,512 and in U.S. patent applications. num. 10 / 424,640 and 10 / 430,617. c-2) Source of stannous ion The oral care agents useful herein include a source of stannous ion. The stannous ions can be generated from stannous fluoride and other stannous salts. It has been found that stannous fluoride contributes to decrease gingivitis, plaque, sensitivity and improvement
the benefits in oral breath. The stannous ions included in a buccal composition will provide efficacy to the subject who uses the composition. Although efficacy could include benefits other than decreased gingivitis, efficacy is defined as a marked degree of decrease in the site of plaque metabolism. Formulations that provide this efficacy generally include stannous levels generated by stannous fluoride or other stannous salts ranging from about 3000 to about 15,000 ppm of stannous ions in the total composition. At stannous levels below about 3000 ppm, the efficiency of the stannous is insufficient. The stannous ion is present in an amount of about 4000 ppm to about 12,000 ppm, in one embodiment, from about 5000 ppm to about 10,000 ppm. Other stannous salts include organic stannous carboxylates, such as stannous acetate, stannous gluconate, stannous oxalate, stannous malonate, stannous citrate, stannous ethylene glycolate, stannous format, stannous sulfate, stannous lactate, stannous tartrate, and the like. Other sources of stannous ion include stannous halides such as stannous chloride, stannous bromide, stannous iodide, and stannous chloride dihydride. In one embodiment, the source of stannous ion is stannous fluoride and in another stannous chloride dihydrate. The combined stannous salts may be present in an amount from about 0.001% to about 11%, by weight of the compositions. In one embodiment, the stannous salts may be present in a concentration of approximately 0.01% at
about 7%, in another embodiment, that concentration may be from about 0.1% to about 5% and in another embodiment from about 1.5% to about 3%, by weight of the composition. c-3) Fluoride ion source Oral care agents useful herein include a fluoride ion source to provide an anticarie effect. These materials include the inorganic fluoride salts, such as the soluble salts of alkali metal fluoride, for example, sodium fluoride, potassium fluoride, sodium monofluorophosphate and sodium hexafluorosilicate. Alkali metal fluorides are preferred, such as sodium fluoride, sodium monofluorophosphate, sodium hexafluorosilicate and mixtures thereof. The amount of fluorine-providing salt is generally present in the oral composition in a concentration of about 0.0 to about 3.0% by weight. Any suitable minimum amount of this salt can be used, but it is preferred to employ enough fluoride salt to release from about 50 ppm to about 3500 ppm, preferably from about 300 ppm to 2,000 ppm, of fluoride ion. c-4) Bleaching agent Oral care agents useful herein include a bleaching agent. Suitable actives for the bleach are selected from the group consisting of alkali metal and alkaline earth metal peroxides, metal chlorites, perborates including mono and tetrahydrates, perfosphates, percarbonates, peroxyacids, alkali metal and persulfates, such as
as ammonium, potassium, sodium and lithium persulfates, and combinations of these. Suitable peroxide compounds include hydrogen peroxide, urea peroxide, calcium peroxide, carbamide peroxide, magnesium peroxide, zinc peroxide, strontium peroxide and mixtures thereof. In one embodiment the peroxide compound is carbamide peroxide. Suitable metal chlorites include calcium chlorite, barium chlorite, magnesium chlorite, lithium chlorite, sodium chlorite, and potassium chlorites. The additional bleaching assets can be hypochlorite and chlorine dioxide. In one embodiment, chlorite is sodium chlorite. In another embodiment, the percarbonate is sodium percarbonate. In one embodiment, the persulphates are oxones. The proportion of these substances depends respectively on the available oxygen or chlorine that the molecule can provide to whiten the stain. In a modality, bleaching agents may be present in a concentration of from about 0.01% to about 40%, in another embodiment, from about 0.1% to about 20%, in another embodiment, from about 0.5% to about 10% and in another embodiment, about 4% to about 7%, by weight of the composition. c-5) Antimicrobial agent Oral care agents useful herein include other antimicrobial agents. These agents may include, but are not limited to: 5-chloro-2- (2,4-dichlorophenoxy) -phenol, commonly referred to as triclosan; 8-hydroxyquinoline and its salts; copper compounds II, even, but without
limited to copper chloride (II), copper sulfate (II), copper acetate (II), copper fluoride (II) and copper hydroxide (II); italic acid and its salts including, but not limited to, those described in U.S. Pat. no. 4,994,262, including monopotassium magnesium phthalate; chlorhexidine; alexidine; hexetidine; sanguinarine; benzalkonium chloride; salicylanilide; domiphen bromide; cetylpyridinium chloride (CPC); tetradecylpyridinium chloride (TPC); N-tetradecyl-4-ethylpyridinium chloride (TDEPC); octenidine; iodo; sulfonamides; Bisbiguanides; phenolic; delmopinol, octapinol and other piperidino derivatives; niacin preparations; zinc or stannous ion agents such as zinc oxide, zinc lactate and zinc citrate; nystatin; grapefruit extract; apple extract; thyme oil; thymol; antibiotics such as augmentin, amoxicillin, tetracycline, doxycycline, minocycline, metronidazole, neomycin, kanamycin, cetylpyridinium chloride, and clindamycin; the analogs and salts of the above; essential oils including thymol, geraniol, carvacrol, citral, hinokitiol, eucalyptol, catechol (particularly 4-allylcatechol) and mixtures thereof; methyl salicylate; hydrogen peroxide; metal salts of chlorite; and the mixtures of all the previous ones. The antimicrobial components can be present from about 0.001% to about 20% by weight of the composition. c-6) Antiplaque agent Oral care agents useful herein include another antiplaque agent such as dimethyl isosorbide, copper salts, strontium salts, magnesium salts or a dimethicone copolyol. The copolyol of
Dimethicone is selected from C12 to C20 alkyldimethicone copolyols and mixtures thereof. In one embodiment, the dimethicone copolyol is copolyol of cetyl dimethicone marketed under the name of Abil EM90. In one embodiment, the dimethicone copolyol may be present in a concentration of from about 0.001% to about 25%, in another embodiment that concentration is from about 0.01% to about 5%, and in another embodiment, from about 0.1% to about 1.5 % by weight of the composition. c-7) Anti-inflammatory agent Oral care agents useful herein include anti-inflammatory agents. These agents may include, but are not limited to, non-steroidal anti-inflammatory agents oxicam, salicylates, propionic acids, acetic acids and fenamates. Non-steroidal anti-inflammatory agents oxicam (NSAIDs) include, but are not limited to, ketorolac, flurbiprofen, ibuprofen, naproxen, indomethacin, diclofenac, etodolac, indomethacin, sulindac, tolmetin, ketoprofen, fenoprofen, piroxicam, nabumetone , aspirin, diflunisal, meclofenamate, mefenamic acid, oxifenbutazone, phenylbutazone and acetaminophen. The use of NSAIDs such as ketorolac is claimed in U.S. Pat. no. 5,626,838. Methods for preventing or treating primary and recurrent squamous cell carcinoma of the oral cavity or oropharynx by topical administration in the oral cavity or oropharynx of an effective amount of
an NSAID. Suitable steroidal anti-inflammatory agents include corticosteroids, such as fluccinolone and hydrocortisone. c-8) Nutrients Oral care agents useful herein include nutrients that improve the condition of the oral cavity. Nutrients include minerals, vitamins, oral nutritional supplements, enteric nutritional supplements and mixtures of these. Useful minerals include calcium, phosphorus, zinc, manganese, potassium and mixtures of these. Vitamins can be included with minerals or they can be used independently. Suitable vitamins include vitamins C and D, thiamine, riboflavin, calcium pantothenate, niacin, folic acid, nicotinamide, pyridoxine, cyanocobalamin, para-aminobenzoic acid, bioflavonoids, and mixtures of these. Other nutritional supplements include amino acids, lipotropics, fish oil and mixtures thereof. The amino acids include, but are not limited to, L-tryptophan, L-lysine, methionine, threonine, levocamitine or L-carnitine and mixtures thereof. Lipotropic agents include, but are not limited to, choline, inositol, betaine, linoleic acid, linolenic acid, and mixtures thereof. Fish oil contains large amounts of polyunsaturated fatty acids Omega-3 (N-3), eicosapentaenoic acid and docosahexaenoic acid. Enteric nutritional supplements include, but are not limited to, protein products, glucose polymers, corn oil, safflower oil, medium chain triglycerides. Minerals, vitamins, oral nutritional supplements and enteric nutritional supplements are described in more detail in Dmg Facts and
Comparisons (brochures of the drug information service), Wolters Kluer Company, St. Louis, Mo., © 1997, pgs. 3-17 and 54-57. c-9) Antioxidants Oral care agents useful herein include antioxidants. Antioxidants are described in texts such as Cadenas and Packer, The Handbook of Antioxidants, ©
1996 by Marcel Dekker, Inc. Antioxidants useful in the present invention include, but are not limited to, vitamin E, ascorbic acid, uric acid, carotenoids, vitamin A, flavonoids and polyphenols, herbal antioxidants, melatonin, aminoindoles, lipoic acids and mixtures of these. c-10) Antiviral Agents Oral care agents useful herein include antiviral actives used to treat viral infections. These viral active agents include, but are not limited to: phosphonoformic acid; ciosin derivatives; purine analogues, such as adenosine, guanosine and inosine analogues; pyrimidine bases, such as cytidine and thymidine; amantadines; rimantadine hydrochloride; ribavirin; zanamivir; oseltamivir phosphate; trifluridine; heterocyclic dyes; acyclovir; famciclovir; valaciclovir, cidofovir; ganciclovir; levimisol; idoxuridine; lipophilic ß-ketones; and thiosemicarbazones. These antiviral assets are described in Drug Facts and Comparisons (brochures of the drug information service), Wolters Kluwer Company, St. Louis, Mo., © 2001, pgs. 1400-1423 (b), and in Kirk-Othmer, Encyclopedia of Chemical Technology
(Encyclopedia of Chemical Technology), Fourth Edition, Volume 3, Wiley-Interscience Publishers (1992), p. 576-607. c-11) Analgesic and anesthetic agents Oral care agents useful herein include pain relieving agents or desensitizers. Analgesics are agents that relieve pain through its action at the central level, which increases the threshold of pain without altering consciousness or other sensory abilities. These agents may include, but are not limited to: strontium chloride; potassium nitrate; sodium fluoride; sodium nitrate; acetanilide; phenacetin; acertofan; tiorfan; Spiradoline; aspirin codeine; Thebaine; levorphenol; hydromorphone; oxymorphone; phenazocine; fentanyl; buprenorphine; butafanol; nalbuphine; pentazocine; natural herbs such as galsal nut; rough cubebine; Galanga skullcap; Liangmianzhen; and Baizhi. Topical anesthetic or analgesic agents, such as acetaminophen, sodium salicylate, trolamine salicylate, lidocaine and benzocaine, may also be present. These analgesic active agents are described in detail in the publication Kirk-Othmer, Encyclopedia of Chemical Technology, fourth edition, volume 2, Wiley-Interscience Publishers (1992), p. 729-737. c-12) Stratified Material Containing Zinc A useful oral care active herein is the stratified material containing zinc, which has an effective antimicrobial and antigingivitis benefit due to the high lability of zinc. Those zinc-containing stratified materials particularly useful herein are those that
they have a relative zinc solubility greater than about 25%, have an average particle size of less than about 20 microns, and have a high surface area. In a preferred embodiment, the zinc-containing stratified material herein is incorporated into compositions containing an anionic surfactant, as discussed below. The lability of zinc is a measure of the chemical availability of the zinc ion. Soluble zinc salts that do not form complexes with other species in solution, have a relative lability of zinc, by definition, of 100%. The use of partially soluble forms of zinc salts or incorporation into a matrix with potential complexing agents usually reduces the lability of zinc practically below of the maximum 100% defined. Labile zinc is maintained by choosing a stratified material containing effective zinc or forming a stratified material containing effective zinc at the site by known methods. Zinc lability is evaluated by combining a diluted solution or dispersion containing zinc with the metallochromic xyleneol orange dye (XO) and measuring the degree of color change under specified conditions. The magnitude of color formation is proportional to the level of labile zinc. The developed procedure has been optimized for aqueous surfactant formulations but can also be adapted to other forms of physical products. A spectrophotometer is used to quantify the color change 572 nm, the wavelength for the optimal color change for XO. The spectrophotometer is adjusted to zero absorbance at 572 nm using a
test control product except that it excludes the potentially labile form of zinc. The control and test products are then treated identically as follows. A 50 μL sample is dispensed into a bottle and 95 mL of distilled and deaerated water is added and stirred. Pipette into the sample vial 5 mL of a 23 mg / mL xyleneol orange stock solution at pH 5.0; this is considered time 0. Then the pH is adjusted to 5. 50 ± 0.01 using diluted HCl or NaOH. After 10.0 minutes, a portion of the sample is filtered (0I45 μ) and the absorbance at 572 nm is measured. The measured absorbance is then compared to a control measured separately to determine the relative lability of zinc (zero to 100%). The 100% lability control is prepared in a matrix similar to the test products but using a soluble zinc material (such as zinc sulfate) incorporated at an equivalent level based on zinc. The absorbance of the 100% lability control is measured equally as measured for the test materials. The relative lability of zinc is preferably greater than about 15%, more preferably greater than about 20%, and even more preferably greater than about 25%. Using this methodology, the following examples demonstrate a material (basic zinc carbonate) having intrinsically high lability in an anionic surfactant system compared to one (znO) with intrinsically low lability.
The stratified structures that contain zinc are those that have a crystalline growth that occurs mainly in two dimensions. It is described in conventional terms that layered structures are not only those in which all atoms are incorporated in well-defined layers, but also those that have ions or molecules between the layers, called gallery ions (AF Wells "Structural Inorganic Chemistry" Clarendon Press, 1975). Zinc-containing stratified materials (ZLM) may have the zinc incorporated in the layers or be components of the gallery ions. Many ZLMs are found in nature as minerals.
Common examples include hydrochlorite (zinc hydroxycarbonate), basic zinc carbonate, auricalcite (copper and zinc hydroxycarbonate), rosesite (copper and zinc hydroxycarbonate) and many related zinc-containing minerals. Natural ZLMs can also be found where species occur. of anionic layers such as clay-type minerals (eg, phyllosilicates) contain ion ions from exchanged ions. These natural materials can also be obtained synthetically or formed in place in a composition or during a production process. Another common class of ZLM, which are often, but not always, synthetic, are double layer hydroxides, which are usually represented
by the formula [M2 + 1-xM3 + x (OH) 2] x + Am-x / m nH2O and some or all of the divalent ions (M2 +) would be represented as zinc ions (Crepaldi, EL, Pava, PC, Tronto, J, Valim, JB J. Colloid Interfac, Sci. 2002, 248, 429 ^ 2). Another class of MLZ, called double hydroxyl salts, can be prepared (Morioka, H., Tagaya, H., Karasu, M, Kadokawa, J, Chiba, K Inorg, Chem. 1999, 38, 4211-6). The double hydroxyl salts can be represented by the general formula [M2 + 1-xM2 + 1 + x (OH) 3 (1-y)] + An- (1 = 3y) / n nH2O where the two metal ions may be different; if they are equal and are represented by zinc, the formula is simplified to [Zn1 + x (OH) 2] 2x + 2x A- nH2O. This last formula represents (where x = 0.4) common materials such as zinc hydroxychloride and zinc hydroxynitrate. These are also related to hydrocintite, where a divalent anion replaces the monovalent anion. These materials can also be formed in place in a composition or in or during a production process. These ZLM classes represent relatively common examples of the general category and are not intended to be limiting in terms of the broader scope of the materials in accordance with this definition. Commercially available sources of basic zinc carbonate include basic zinc carbonate (Cater Chemicals: Bensenville, IL, USA), zinc carbonate (Shepherd Chemicals: Norwood, OH, USA), zinc carbonate (CPS Union Corp .: New York, NY, USA), zinc carbonate ( Elementis Pigments: Durham, UK), and AC zinc carbonate (Bruggemann Chemical: Newtown Square, PA, USA).
Basic zinc carbonate, which may also be commercially referred to as "zinc carbonate" or "basic zinc carbonate" or "zinc hydroxycarbonate", is a synthetic version comprising materials similar to hydrocintite. The idealized stoichiometry is represented by Zn5 (OH) 6 (CO3) 2, but the actual stoichiometric ratios may vary slightly, and other impurities may be incorporated in the crystal lattice. d) Polar solvent carrier The composition of the present invention comprises a polar solvent carrier to supply the essential components, and to provide an adequate rheology with the hydrophilic clay material. The polar solvent also serves as a solvent for incorporating oral care actives and other water soluble components. The polar solvent is included, by weight of the total composition, from about 1% to about 95%, preferably from about 30% to about 70%. The polar solvents useful herein include water, polyhydric alcohols such as glycerin, 1,3-butylene glycol, propylene glycol, hexylene glycol, propanediol, ethylene glycol, diethylene glycol, dipropylene glycol, diglycerin, sorbitol, and other sugars that are in liquid form at room temperature. Also useful herein are water-soluble alkoxylated nonionic polymers such as polyethylene glycol. In a preferred embodiment, the present composition may comprise a relatively high level of water to provide a product
profitable. In this preferred embodiment, water is included in an amount of from about 30% to about 95%, more preferably from about 50% to about 70% of the total composition. Polar solvents commercially available herein include: glycerin available from Asahi Denka; propylene glycol with the trade name LEXOL PG-865/855 available from Inolex, 1, 2-propylene glycol USP available from BASF; 1,3-butylene glycol available from Daisel Kagaku Kogyo; dipropylene glycol with the same trade name available from BASF; diglycerin with the trade name diglycerol available from Solvay GmbH, polyethylene glycol under the trade name PEG 300 available from Doe Chemical Company, and 70% sorbitol solution available from Khalista (Liuzhou) Chemical Industries, Ltd. Free of abrasive material The composition of the present invention is practically free of abrasive material. Specifically, the composition of the present invention has no deliberately included abrasive material. Surprisingly, it has been discovered that the present invention can provide the benefits of a regular dentifrice composition, including those normally attributed to the use of abrasive material, such as cleaning, stain removal, plaque removal, tartar removal, and others. The absence of abrasive material also takes into account the inclusion of certain active agents, such as cetylpyridinium chloride, which otherwise have poor compatibility with abrasive materials, such as silica, and therefore can not be included in a dentifrice composition. Further,
Due to the absence of abrasive material, various characteristics can be sought for the toothpaste product. For example, a composition with a transparent appearance can be made. Abrasive materials of which the present composition is practically free are defined as materials having a DOA value of not more than about 150 mL / 100 g, preferably not more than about 100 mL / 100 g, and have a particle size of about 5. μm to approximately 50 μm. The abrasive materials herein can be distinguished from the materials useful as binders. The materials from which the present invention is free include: inorganic minerals such as gels and silica precipitates; aluminas; hydrated alumina, calcium carbonate, titanium dioxide, talcum, calcium dioxide, and resinous abrasive materials such as particulate condensation products of urea and formaldehyde. Additional binder material The composition of the present invention may further comprise an additional binder material that further contributes rheology to the composition, or provide some mouth feel when used. When included, the additional binder material is selected from those that are compatible with the hydrophilic clay material, and are included so that the total amount of hydrophilic clay material and additional binder material is from about 0.1% to about 10% of the composition. total, and provides a viscosity of approximately 10,000 Pa.sa
approximately 450,000 Pas, preferably from approximately 10,000 Pa.s to approximately 250,000 Pa.s. The modified cellulose polymers are binder materials useful herein to build a continuous structure to the composition. Modified cellulose polymers useful herein include sodium carboxymethylcellulose, polyvinylpyrrolidone, hydroxyethylpropylcellulose, hydroxybutylmethylcellulose, hydroxypropylmethylcellulose, and hydroxyethylcellulose. Particularly useful commercially available materials include sodium carboxymethyl cellulose with the trade name BLANOSE series, OPTICEL 100, and AQUALON series from Hercules; hydroxyethylpropylcellulose with the trade name KLUCEL series of Hercules, hydroxypropylmethylcellulose with the trade name TF-E25 of YIXING CITY NO.8 CHEMICAL PLANT and with the trade name BENECEL series of Hercules. Carboxyvinyl anionic polymers are binder materials useful herein to construct a three-dimensional structure in combination with the hydrophilic clay materials described above. The carboxy vinyl anionic polymers useful herein include those bearing the trademark CARBOPOL (or carbomer) series such as CARBOPOL 956, 934, 940, 941, 1342, ETD 2020, ULTREZ 10"from Noveon Inc., CARBOPOL 934, 940 , 974 P from BF Goodrich and SYNTHALEN K available from 3V Company The anionic polymers derived from natural rubber are binding materials useful herein to add effectively
viscosity. Anionic polymers derived from natural rubber useful herein include carrageenan, xanthan gum, gelana gum, and locust bean gum. Particularly useful commercially available materials include xanthan gum under the tradename KELDENT series available from CP Kelco, and under the tradename RHODICARE series from Rhodia; gelana gum with the trade name KELCOGEL series of CP Kelco; and locust bean gum with the trade name GELLOID LB series from FMC BioPolymer. Other binder materials useful herein are starch and carrageenan. Carrageenan is commercially available under the trade name VISCARI series and GELCARIN series from FMC BioPolymer, under the trade name MEYPRO-SOL series from Meyhall AG, and under the trade name GENUVISCO series, GENU series and GENUTINE series from CP Kelco.
Additional components The composition of the present invention may include other additional components, which may be chosen by the technician according to the desired characteristics of the final product and which are suitable for making the cosmetic or aesthetically acceptable composition or to provide them with additional use benefits . These additional components are generally used individually at levels no greater than about 5% by weight of the composition. Surfactants may be incorporated into the components of the present invention, as an ingredient to aid in the complete dispersion of the toothpaste throughout the oral cavity when applied to it,
as well as to improve cosmetic acceptability and foaming properties. The surfactants that can be included in the present composition include anionic, nonionic, or amphoteric compounds, with anionic compounds being preferred. Suitable examples of anionic surfactants are higher alkyl sulfates such as sodium or potassium lauryl sulfate, of which monoglycerides of higher fatty acid monoglycerides are preferred, such as the monoglyceride salt of hydrogenated coconut oil fatty acid monoglyceride, alkylsulfonates such as sodium dodecylbenzenesulfonate, higher fatty sulphoacetates, higher fatty acid esters of 1,2-dihydroxypropanesulfonate. Examples of water-soluble nonionic surfactants are the condensation products of ethylene oxide with various hydrogen-containing compounds which are reactive with them and which have long hydrophobic chains (e.g., aliphatic chains of about 12 to 20 carbon atoms), whose condensation products contain hydrophilic polyoxyethylene entities, such as condensation products of poly (ethylene oxide) with fatty acids, fatty alcohols, fatty amides and other fatty entities, and with propylene oxide and polypropylene oxides, for example, Pluronic materials such as Pluronic F127. The surfactant may be present in the present composition in a concentration of from about 0.5 to about 10.0% by weight, preferably from about 1 to about 2% by weight.
Other ingredients that can be incorporated into the dentifrice composition of the present invention include pigments, colorants, flavoring materials and sweeteners. For example, a striped product according to the present invention is obtained in which dyes of contrasting colors are incorporated in each of the components used in the practice of the present invention, the dyes are pharmacologically and physiologically non-toxic when used in the Suggested amounts The colorants used in the present invention include both pigments and colorants. Pigments useful in the present invention include water-insoluble non-toxic pigments, such as titanium dioxide and chromium oxide greens, ultramarine blue and pink and ferric oxides as well as water-insoluble coloring lakes prepared by spreading calcium or aluminum salts of dyes FD &C in alumina, such as green lacquer green FD &C # 1, lacquer FD &C blue # 2, lacquer FD &C R & D # 30, lacquers FD &C # 5 yellow &FD &C # yellow 15 The concentration of the colorant in the present invention is no greater than about 3% by weight. The pigments in the present invention are distinguished from abrasive materials, of which the present composition is practically free, as pigments herein have a particle size in the range of 100 to about 1000 microns, preferably from about 250 to about 500 microns. When present, the pigments are included in the present composition from about 0.5% to about 3% by weight.
Any flavoring or sweetening material may also be incorporated into the components of the present invention. Examples of suitable flavoring constituents are the flavoring oils, for example, the oils of peppermint, peppermint, pyrol, sassafras, clove, sage, eucalyptus, marjoram, cinnamon, lemon, orange, and methyl salicylate. Suitable sweetening agents include sucrose, lactose, maltose, sorbitol, xylitol, sodium cyclamate, perillartin, and sodium saccharin. Conveniently, the flavoring and sweetening agents may together comprise from 0.01% to 5% by weight or more of the preparations. An inhibitor of enzymes, botanical extracts, natural herbal extracts, and others may be included.
EXAMPLES The following examples describe and demonstrate the preferred embodiments that are within the scope of the present invention. The examples are presented for purposes of illustration only, and should not be construed as limitations of the present invention, since many variations thereof are possible without departing from the spirit and scope of the present invention. The following dentifrice compositions are formed by the following components using the preparation method described herein.
Compositions for Examples 1-5 '
Compositions for Examples 6-10
Definition of components * 1 Sodium fluoride: NaF, available from Jinan Chemical Industry Co. Ltd. * 2 Sorbitol (70% solution): 70% Sorbitol solution, available from Khalista (Liuzhou) Chemicals Industries Ltd. * 3 Glycerin : Glycerin, available from Asahi Denka * 4 Polyethylene glycol: PEG-300, available from Doe Chemical Company * 5 Sodium lauryl sulfate (28% solution): SLSS, available from Rhodia Specialty Chemical Wuxi Co. Ltd * 6 Sodium carboxymethylcellulose: CMC, Available from Zhangjiagang city Sanhui Chemical Industry Co., Ltd
* 7 Carbopol: Carbomer 956, available from Noveon, Inc. * 8 Xanthan Gum: KELDENT, available from CP Kelco Inc. * 9 Carrageenan: GELCARIN TP911 available from FMC
Corporation, Division of food ingredients * 10 0.2% Magnesium fluorosilicate stratified synthesized:
LAPONITE DF, available from Rockwood Additives Limited * 11 Synthesized stratified magnesium silicate: LAPONITE D, available from Rockwood Additives Limited * 12 Precipitated amorphous silica: Zeodent 165, available from J. M. Huber Company * 13 Fumed silica: AEROSOL, available from Cabot &
Degussa Corporation * 14 Mica, Coated titanium dioxide: available from Roña * 15 Sodium hydroxide (50% solution): 50% NaOH, available from Guangzhou Chemical Company. * 16 Tetrasodium Pyrophosphate: Tetrasodium Pyrophosphate Anhydrous, available from Lianyungang Duoling Fine Chemical Co. Ltd. * 17 Monobasic Sodium Phosphate Monohydrate: MSP, available from Jiangsu Chengxing Phosphate Chemical Co. Ltd * 18 Trisodic Sodium Phosphate: TSP, available from Jiangsu
Jiangyin Phosph Chemicals * 19 Sodium phytate (20% solution): available from Sichuan
Chengdu Yason
* 20 Saccharin sodium: available from Suzhou Fine Chemical * 21 Stannous fluoride: SnF2, available from Hashimoto * 22 Triclosan: available from Ciba-Geigy Chemicals Ltd. * 23 Cetylpyridinium Chloride: available from Cambrex company * 24 Zinc Carbonate: available from Bruggemann Chemical
Preparation Method The dentifrice compositions of Examples 1-10 can be manufactured by any method known to those experienced in the industry, and are conveniently prepared as follows. First, the hydrophilic clay material (component numbers 10-13) is dissolved in water in a container at room temperature, using a helix mixer until homogenous. In a separate main mixing vessel, the sorbitol solution (component number 2), glycerin (component number 3), polyethylene glycol (component number 4), sodium hydroxide solution (component number 15), dye and pigment (number of component 14) as they are present in the composition, the remaining part of water, are mixed together in a stirrer at a rotation speed of 2.6 rad / s (25 rpm) at 3.7 rad / s (35 rpm) at temperature elevated All remaining components except the flavor and the surfactant (component number 5) are added to the main mixing vessel. The container is sealed, a vacuum of about 13.3 kPa (100 mmHg) is created, the homogenizer is turned on
rotation speed from 251.3 rad / s (2400 rpm) to 366.5 rad / s (3500 rpm). The mixture obtained is further aerated. To this is added the mixture made in the first step. The obtained mixture is mixed and deaerated. Finally, the flavor and surfactant is added (number of component 5), and the container is closed again hermetically, mixed by the homogenizer at a rotation speed of 2251.3 rad / s (400 rpm) at 366.5 rad / s (3500 rpm) for final homogenization, and de-aerated. The product obtained is pumped out of the package and is supplied to a primary package such as a laminar tube. The illustrative compositions herein have many suitable benefits for a dentrifric product. All compositions provide less abrasion to the surface of the teeth, and are safer to the enamel of the teeth compared to toothpastes containing abrasive material. All compositions provide soft oral feel, easy dispersion, and better range in the area between the teeth compared to toothpastes containing abrasive material. All compositions provide the consumer with better taste perception compared to toothpastes containing abrasive material and the same level of the same flavoring. In addition, all compositions can be manufactured at an economical cost. The compositions of Examples 1-5 provide anticarie, antiplaque, bleach, and antitartar benefits. The compositions of Examples 6-7 provide anticarie benefits,
antiplaque, bleach, antisharper, and antigingivitis. The compositions of Examples 8-9 provide anticarie, antiplaque, bleach, antisera, and antimicrobial benefits. The composition of Example 10 provides anticarie, antiplaque, and antitartar benefits. The dimensions and values set forth herein are not to be construed as strictly limited to the exact numerical values mentioned. Instead, unless otherwise specified, each of these dimensions will mean both the mentioned value and also a functionally equivalent range that encompasses that value. For example, a dimension expressed as "40 mm" will be understood as "approximately 40 mm". All documents cited in the Detailed Description of the Invention are incorporated, in the relevant part, as reference herein. The mention of any document should not be construed as an admission that it corresponds to a preceding industry with respect to the present invention. To the extent that any meaning or definition of a term in this written document contradicts any meaning or definition of the term in a document incorporated by reference, the meaning or definition assigned to the term in this written document shall govern. While particular embodiments of the present invention have been illustrated and described, it will be apparent to those skilled in the industry that various other changes and modifications may be made without departing from the spirit and scope of the invention. The intention, therefore, is to
cover in the appended claims all the changes and modifications that
they are within the scope of the invention.
Claims (13)
1. A dentifrice composition comprising: (a) a hydrophilic clay material; (b) a phytic acid compound; (c) an effective amount of an oral care asset; and (d) a polar solvent carrier; wherein the composition is practically free of abrasive material. The dentifrice composition of claim 1 comprising: (a) from about 0.1% to about 10% of the hydrophilic clay material; and (b) from about 0.01% to about 20% of the phytic acid compound. 3. The dentifrice composition of claim 1 wherein the hydrophilic clay material is selected from the group comprising natural and synthesized layered silicate minerals, pyrogenic silicas, precipitated thickening silica, and mixtures thereof. 4. The dentifrice composition of claim 3 wherein the hydrophilic clay material is a synthesized layered magnesium silicate. 5. The dentifrice composition of claim 1 further comprising an additional binder material selected from the group formed of modified cellulose polymers, carboxyvinyl polymers, anionic polymers derived from natural rubber, and mixtures thereof. 6. The dentifrice composition of claim 1 wherein the oral care active is selected from the group consisting of anticalculus agents, stannous ion sources, fluoride ion sources, bleaching agents, antimicrobial agents, antiplaque agents, anti-inflammatory agents, nutrients, antioxidants. , antiviral agents, analgesics and anesthetics, stratified material containing zinc, and mixtures of these. 7. The dentifrice composition of claim 6 wherein the oral care active is selected from the group consisting of fluoride ion sources, stannous ion sources, pyrophosphate salts, polyphosphate salts, hydrogen peroxide, triclosan, and mixtures thereof. . 8. The dentifrice composition of claim 6 wherein the oral care active is an anticarie active selected from the group consisting of cetylpyridinium chloride, sources of stannous ion, and mixtures thereof. 9. The dentifrice composition of claim 6 wherein the oral care active is a stratified material containing zinc having a relative lability of zinc greater than about 25%. The dentifrice composition of claim 9 wherein the layered zinc-containing material is selected from the group consisting of basic zinc carbonate, zinc hydroxycarbonate, copper and zinc hydroxycarbonate, auricalcite, copper and zinc hydroxycarbonate, rosesite, phyllosilicate containing zinc ions, double stratified hydroxide, double hydroxyl salts, and mixtures thereof. 11. The dentifrice composition of claim 9 wherein the stratified material containing zinc is basic zinc carbonate. The dentifrice composition of claim 1 wherein the polar solvent carrier comprises, by weight of the total composition, from about 30% to about 95% water. 13. A method for cleaning the teeth without the use of abrasive material comprising the steps of brushing the teeth with the dentifrice composition of claim 1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/740,538 | 2005-11-29 | ||
US60/751,405 | 2005-12-16 | ||
US11545266 | 2006-10-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2008006887A true MX2008006887A (en) | 2008-09-02 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009519235A (en) | Dentifrice composition comprising a binder system comprising a hydrophilic clay material | |
US20070122359A1 (en) | Dentifrice composition comprising binder system comprising hydrophilic clay material | |
JP2009513695A (en) | Dentifrice composition without abrasives | |
JP4030104B2 (en) | Oral care kit and oral care composition | |
US20070122358A1 (en) | Dentifrice composition free of abrasive material | |
AU2010365781B2 (en) | Films and compositions comprising the same | |
US20070254067A1 (en) | Consumer customizable oral care products | |
CA2591847A1 (en) | Two phase whitening oral care composition | |
US20050207997A1 (en) | Dual component dentifrices and methods of whitening using the same | |
CN101316571A (en) | Dentifrice composition free of abrasive material | |
AU2012397212B2 (en) | Oral care composition containing ionic liquids | |
MX2008006887A (en) | Dentifrice composition free of abrasive material |